BioProcess Technology Consultants Appoints Glacken as Senior Consultant and Davidovits as Associate Consultant
WOBURN, MASSACHUSETTS, November 13, 2014— Bioprocess Technology Consultants, Inc. (BPTC), the leading strategic, technical, quality, and regulatory consulting company for the global biopharmaceutical industry, has appointed Michael W. Glacken, Sc.D., as a Senior Consultant and Terence Davidovits, M.Eng., as an Associate Consultant.
Dr. Glacken has 25 years of experience in developing efficient manufacturing processes for biological products spanning all phases of product development. He was most recently Vice President of Operations at Joule Unlimited, where he headed development of proprietary large-scale photosynthetic bioreactors. Previously, he led Chemistry, Manufacturing, and Controls (CMC) development at biopharmaceutical companies including Millennium Pharmaceuticals, Bristol Myers Squibb, and SmithKline Beecham. He received his B.S. in Chemical Engineering from the University of Maryland, and his Sc.D. in Biochemical Engineering from the Massachusetts Institute of Technology.
“We are thrilled to bring such an accomplished CMC executive to our team,” said Dr. Howard Levine, President of BPTC. “Mike’s breadth of experience leading late-stage development and commercialization programs will be invaluable to our clients preparing for commercialization or post-approval process changes.”
Mr. Davidovits is a chemical engineer with a strong background in quantitative modeling and expertise in designing, costing, and building capital projects. He has extensive experience creating cost of goods models, developing capital requirements for new projects, and assessing economic feasibility of disruptive technologies. Before joining BPTC, he was Senior Engineer at Pronutria, where he led a team developing cost models for nutraceuticals. He holds an M. Eng. degree in Chemical Engineering and a B.S. in Mechanical Engineering from Cornell University.
“Terence’s solid engineering background and modeling expertise will help clients forecast commercial-scale production costs as well as weigh the costs of changing processes or adopting new technologies,” said Thomas C. Ransohoff, Vice President of BPTC. “His addition to the BPTC team strengthens our modeling capabilities and allows us to support a wider range of modeling projects.”
About BioProcess Technology Consultants
Founded in 1994, BPTC is the recognized worldwide leader in biologics Chemistry, Manufacturing, and Controls (CMC) consulting, providing a full range of technical, regulatory, and strategic assistance to pharmaceutical and biotechnology companies in the development and commercialization of biopharmaceutical products. The company works with clients globally to find and apply solutions to the challenges of biopharmaceutical product development from clone to commercial®. BPTC helps develop manufacturing processes and strategies that enhance the overall value of client companies and accelerate the advancement of new products from clone to clinic®. BPTC also helps investors make informed decisions by providing technical and business evaluations of new products and technologies and product discovery, development, and commercialization plans of potential investments and existing portfolio companies. For more information about BPTC, visit http://www.bptc.com and follow the Company on Twitter at bptcGlobal or LinkedIn at http://www.linkedin.com/company/bioprocess-technology-consultants-inc.